ACT GENOMICS CO., LTD.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
SOLUTION -
1. Genomic Tests
2. For Professionals
3. For Patients
4. For Biopharma
1. Genomic Tests
2. For Professionals
3. For Patients
4. For Biopharma
Founded Year
2013
Unified Business No.
54650959
Status
Active
Number of Employees
0
Total Paid-in
Capital
455,080,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Acquired(2025)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
ACT Genomics is an award-winning cancer solution provider founded in 2014 by a small group of scientists from academia. With our name, ACT Genomics, reflecting our passion to “turn genomics into action”, we set out to apply academic theories in clinical practice and truly make personalized cancer care accessible to all.
Over the years, our practical experience has helped academic research make remarkable progress, which has in turn enhanced our cancer solutions with high efficiency and accuracy. As a pioneer in Taiwan and the wider Asian region, we are committed to empowering cancer patients with advanced genomic treatments and continuing to make strides forward in precision medicine.
Over the years, our practical experience has helped academic research make remarkable progress, which has in turn enhanced our cancer solutions with high efficiency and accuracy. As a pioneer in Taiwan and the wider Asian region, we are committed to empowering cancer patients with advanced genomic treatments and continuing to make strides forward in precision medicine.
